Substituted pyridines



it W Pat Q 3,409,629 SUBSTITUTED PYRIDINES John H. Biel and Edward J. Warawa, Milwaukee, Wis., assignors to Aldrich Chemical Co pany, Inc., Milwaukee, Wis., a corporation of Wisconsin No Drawing. Filed Sept. 15, 1964, Ser. No. 396,735 j 9-Claims. (Cl. 2602 97) a jt W. iii mxmmfm; uIscLosUiiE I... Substituted py-iidines'having hypocholesteremic activity are useful -'for lowering blood cholesterol-Jlevels.

"This invention relates to novel'compounds' More par ticularlyy this invention relates to novel 'compounds which possess valuable"- utility as hypocholesteremic agentsjIn another aspect, this invention relates to anovel method of lowering blood'cholesterol level.

. It'is an object of this invention to provide a new class of chemical compounds. It is another object of the pressentinvention to provide novel compounds having hypocholesteremic activity; -It is a further "object of the prese'nfiinvntio'n to' provide a novel method of lowering blood cholesterol level. These and other objects which mayappear as the specification proceeds are achieved by this invention which comprises the provision of compounds selected from the group consisting of compounds having the'followingforniula v v Y and the pharmaceutically acceptable nontoxic salts thereof. In Formula I,

R R and R each represent a member selected from the group; consisting of hydrogen, chloro, bromo, iodo, fiuoro, trifiuoromethyl, (lower) alkyl, (lower) alkoxy, (lower) alkylthio, di (lower) alkylamino, di( lower) alkylsulfamyl, methylenedioxy, (lower)alkanoyl, phenyl, phenoxy, benzyl and cycloalkyl radicals having from 5 to 7 carbon atoms inclusive, e.g. cyclopentyl, cyclohexyl and cycloheptyl.

The pharmaceutically acceptable nontoxic salts include the organic and inorganic acid addition salts, e.g., those prepared from acids such as hydrochloric, sulfuric, sulfamic, tartaric, fumaric, hydrobromic, hydriodic, glycolic, citric, maleic, phosphoric, succinic, acetic, nitric and the like.

3,409,529 Patented Nov. 5,

Preferred compounds of the present invention those having the following formula v (m v H Still more preferred compounds of the present invention are those having the following formula The compounds of this invention are valuable pharmaceutical agents. They produce a reduction in the serum cholesterol level which makes the compounds useful as hypocholesteremic agents. Thus, the compounds can be used for the treatment of hypercholesteremia.

The compounds of the present invention are produced in the following manner. The tertiary alcohols of Formula I are prepared by the reaction of a benzyl pyridyl ketone of the formula 0 I -CHz- \N g wherein R and R are as represented above, with a Grignard reagent, i.e., an aryl magnesium halide of the formula HalMg-S g wherein Hal is chloro, bromo or iodo, and R and R are as represented above, or an organo-lithium compound of the formula (VII) wherein R and R are as represented above. The reaction is carried out-in the presence of an inert solvent, tetrahydrofuran, at reflux temperature. Such procedures are described in the following references: Chem. Abstr.

Z-pyridyl 4-chlorobenzyl ketone,

3-pyridyl 3-bromobenzyl ketone,

4-pyridyl Z-fluorobenzyl ketone,

Z-pyridyl 4-methoxybenzyl ketone,

2-pyridyl 3,4-methylenedioxybenzyl ketone, 2-pyridyl 3,4-dichlorobenzyl ketone, 2-pyridyl 3 -methoxy-4-chlorobenz-yl ketone, 4-pyridyl 3 methoxy-4-chlorobenzyl ketone, 3-pyridyl 3-trifluoromethyl-4-phenylbenzyl ketone, 4-pyridyl 3-trifiuoromethylbenzyl ketone and Z-pyridyl benzyl lcetone.

Representative of the tertiary alcohols of this invention which may be produced in the foregoing manner are 1- (2-pyridyl l- (3-trifluoromethylphenyl) -2-phen-yl ethanol,

1- (3'pyridyl) 1- (3-trifluoromethylphenyl) -2-phenylethanol,

1- (4-py ridyl) l- (3-trifluoromethylphenyl) -2-phenylethanol,

1- 2-pyridy1) l- (4-trifluoromethylphenyl) -2-p'henylethanol,

1- (3-pyridyl) l- (3 -trifluoromethylphenyl) -2- (4-chlorophenyl) ethanol,

1- (4-pyridyl) l- (4-trifluoromethylphenyl) -2-phenylethanol,

1- (4-pyridyl) 1- (3-trifluoromethylphenyl) -3- (4-chlorophenyl) -ethanol,

1- (Z-pyridyl) l- (Z-trifluoromethylphenyl) -2- (4-chlorophenyl) -ethanol,

1- (4-pyridyl) l- 3 -trifluoromethylphenyl) -2- (4-tolyl) ethanol,

1- Z-pyridyl) 1- Z-trifluoromethylphenyl) -2- (4-chlorophenyl) ethanol,

1- (Z-pyridyl) l- (S-trifluorornethylphenyl) -2- (4-methoxyphenyl) ethanol,

l-(4-pyridyl)-1-(3-trifluoromethylphenyl)-2-(4-rnethoxyphenyl)ethanol,

1- (Z-pyridyl) 1- (3-trifluoromethylphenyl) -2- (4-brolmophenyl) ethanol,

1- (2-pyridyl) 1- (3-trifluoromethyl-4-chlorophenyl) -2- phenylethanol and 1- (4-pyridyl) -1 (B-trifluoromethylphenyl) -2- (4-trifiuoromethylphenyl) ethanol.

The starting materials used in the processes described herein are compounds which are either commercially available, well-known in the art, or easily prepared in accordance with standard organic procedures previously described in the chemical literature.

The compounds of this invention may be administered as the free bases or in the form of their nontoxic addition salts. They may be compounded and formulated into pharmaceutical preparations in unit dosage form for oral or parenteral administration with organic or inorganic solid materials or liquids which are pharmaceutically acceptable carriers. The compositions may take the form of tablets, powder granules, capsules, suspensions, solutions and the like. Such compositions are considered within the scope of this invention.

The compositions of this invention when administered orally or parenterally in an effective amount are efiective in the treatment of hypercholesterolemia.

The following examples are intended to illustrate the invention described herein Without unduly restricting it.

Example l.-Preparation of 1-(2-pyridyl)-l-(3- trifiuoromethylphenyl)-2-phenylethanol B-tritluoromethylphenyl magnesium bromide was prepared by adding 7.9 :gm. of magnesium ,and 70.9 gm. of 3-trifluoromethylbromo-benzene to ether, 2-pyridyl benzene ketone (59.1 gm.) was then added dropwise and refluxed overnight. After cooling, m1; of ice water was added, the supernatant liquid was decanted, and the residue was filtered through Celite earth). The filtered material was then stirred with more ether, and filtered (3 times). Ether was removed from the combined ether extract in vacuo, and the residue was extracted with methylene chloride, dried, and filtered. Removal of solvent left a residue which was crystallized from hot heptane. The solid was treated with 23 gm. (0.15 mol) of Girard T reagent in 230 ml. ethanol and 23 m1. acetic acid. After refluxing for 2 hours, the solution was cooled, made alkaline with sodium hydroxide solution, and extracted with methylene chloride, dried, and filtered. Removal of solvent left 75.4 gm. of the product, l-(2-pyridyl) 1-(3-trifluoromethylphenyl)-2-phenylethanol. The product was found not to contain the carbonyl group by infrared analysis.

The product was converted to the hydrochloride salt with gaseous hydrogen chloride in ethanol. The hydrochlophenylethanol after recrystallization from isopropanol had C., and the following ele- Example 2 When, in the procedure of Example 1, 2-pyridyl benzyl ketone is replaced by an equal molar amount of 3-pyridyl benzyl ketone,

4-pyridyl benzyl ketone, 2-pyridyl-4-trifluoromethylbenzyl ketone, 3-pyridyl-4-chlorobenzyl ketone, Z-pyridyl-Z-bromobenzyl ketone, 2-pyridyl-3-iodobenzyl ketone, 2-pyridyl-2,4-dichlorobenzyl ketone, 2-pyridyl-4-fluorobenzyl ketone, 2-pyridy1-3-trifluoromethylbenzy1 ketone, 4-pyridyl-4-methylbenzyl ketone, 2-pyridyl-3-mcthylbenzyl ketone, 2-pyridyl-4-ethylbenzy1 ketone, 3-pyridyl-2-butylbenzyl ketone, 2-pyridyl-3-methoxybenzyl ketone, 2-pyridyl-2,6-dimethylbenzyl ketone, 2-pyridyl-4-methylthiobenzyl ketone, 3-pyridyl-4-trifluoromethylbenzyl ketone, 2-pyridy1-3-cyclohexylbenzyl ketone, 2-pyridyl-4-phenylbenzyl ketone, 3-pyridyl-4-phenoxybenzyl ketone, 2-pyridyl-4-benzylbenzyl ketone, 2-pyridyl-2-acetylbenzyl ketone, 2-pyridyl-3-dimethylsulfamylbenzyl ketone, 3-pyridyl-2,3-methylenedioxybenzyl ketone, 4-pyridyl-3-dirnethylaminobenzyl ketone, 2-pyridyl-2-ethoxybenzyl ketone, 2-pyridyl-3-cyclopentylbenzyl ketone and 2-pyridyl-2-methyl-4-trifiuoromethylbenzyl ketone, respectively, there are obtained,

l-(3-pyridyl-1-(3-trifiuoromethylphenyl)-2- phenylethanol,

. (diatomaceous 7; Example 4 When, in the procedure of Example 1, 2-pyridyl benzyl ketone is replaced by an equal molar, amount of 3,-pyridyl benzyl ketone and 3 ;trilluoromethylphenyl magnesium bromide is replaced by an equal molar amount of 2-,trifluoromethylphenyl- ,magnesium ,bromide, there is Lobtained 1 (3 pyridyl) 1'- (2 trifluoromet-hylphenyD-Z- phenylethanol. I I

Example 5 A When, in thepr'ocedure 'of'Exar'nple 1, Z-pyridyl benzyl ketone is replaced by an equal molar amount of 4- pyridyl benzyl ketone and '3-trifluorbmethylphe'nyl magnesium bromide is replaced by an equal molor' amount of Z-trifluoromethylphenyl magnesium bromide, there is obtained l (4 pyridyl) 1 (2 trifiuoromthylphenyD-Z- Phenylethanol.

4 Example 6 When, in the procedure of Example 1, Z-pyridyl benzyl ketorie is replaced by an equal-molar amount of 3-pyridyl benzyl ketone and 3-trifluoromethylphenyl magnesium bromide is replaced by an equal molar amount of 4-trifiuoromethylphenyl magnesium bromide, there is obtained 1 (3 -'pyridyl) l (4 trifluoromethylphenyl) 2 phenylethanol. 7

Example 7 When, in the procedure of Example 1, 2-pyridyl benzyl ketone is replaced by an ,equal molar amount of 4-pyridyl benzyl ketone and 3-trifiuoromethylpheny1 magnesium bromideis; replaced by an equal molar amount of 4-trifluoromethylphenyl magnesium bromide, there is obtained 1 (4 pyridyl) l (4,-, trifluoromethylphenyl) 2- phenylethanol.

Thus, it is apparent from the foregoing description that the objects of this invention have been attained. Novel compounds ,have been invented which have hypocholesteremic activity. In addition, a novel method of treating hyperchloesteremia has been invented.

While this invention has been described and exemplified in terms of its preferred embodiment, those skilled in the art will appreciate that modifications can be made without departing form the spirit and scope of this invention.

What is claimed is:

1. A compound selected from the group consisting of compounds of the formula I gi g ing 8 2. A compoundof the formula 9 9. The compound having the formula 10 References Cited Wright et al.: J. Med. Chem, vol, 7, pp. 113115, January 1964, RSI. J5. 5 Yale: J. Med. Chem, Vol. 1, pp. 121 and 130 (February 1959), RSI. J5.

HENRY R. JILES, Primary Examiner.

0 A. L. ROTMAN, Assistant Examiner. 

